<p><strong>Professor Mary Anne O’Connell has spent decades at the forefront of RNA biology, helping uncover how cells distinguish their own RNA from foreign genetic material. Her research on ADAR enzymes and RNA editing has shaped our understanding of immunity, inflammation, and the future of RNA-based therapies. Before joining CEITEC Masaryk University, she worked in research institutions across the United States, Switzerland, Sweden, and the United Kingdom. In this interview, she reflects on scientific turning points, the emotional realities of leading a research group, the evolution of RNA research, and the importance of resilience –&nbsp;in science and in life.</strong></p><h5><strong>You originally worked on microbiology before moving into RNA research. How difficult was that transition, and are such shifts common in scientific careers?</strong></h5><p>Quite naturally, actually. During my PhD, HIV was emerging in New York, and many people from my generation moved into retrovirus research because it felt urgent and important. I worked at <strong>Albert Einstein College of Medicine in New York</strong>, where some of the first HIV cases appeared at the neighbouring large hospital. Therefore, I went to<strong> MIT</strong> to do a postdoc with <strong>Nancy Hopkins</strong>, who was a leader in the field of murine retroviruses.</p><p>Then my husband wanted to return to Europe, to Switzerland in particular. I found a position in the laboratory of <strong>Walter Keller in the Biozentrum in Basel </strong>and had an opportunity to study RNA and viruses. I took that position — though I never worked on viruses, I began my research on ADAR enzymes.</p><p>In science, these shifts happen often. Careers are shaped not only by curiosity, but also by circumstances; timing, funding, countries, and family. Often the path only makes sense in retrospect.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Jdi_do_toho_i_kdyz_ti_rozum_rika_ne_U_kavy_s_Mary_Anne_O_Connell_3_d97466b112.jpeg" alt="CEITEC: Walk on Air Against Your Better Judgment. Over Coffee with Mary Anne O’Connell: Mary Anne O’Connell" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Jdi_do_toho_i_kdyz_ti_rozum_rika_ne_U_kavy_s_Mary_Anne_O_Connell_3_d97466b112.jpeg 234w," sizes="100vw" width="1600" height="1068"></p><h5><strong>Was there a particular moment when you realised you had chosen the right career?</strong></h5><p>Yes. After my PhD, I wasn’t sure I wanted to stay in science. I travelled alone through Nepal and India and did the Annapurna trek. When I came down from the mountains, I picked up <i>The Herald Tribune</i>. The first thing I read was a science article, and I remember thinking immediately: “Okay. This is it.” It sounds strange, but that was the moment. It felt as if the universe was quietly pointing me in the right direction.</p><h5><strong>How would you explain RNA editing and ADAR enzymes to a non-specialist?</strong></h5><p>DNA is the genetic blueprint of our cells. RNA is the intermediate step between DNA and proteins.</p><p>For a long time, scientists thought RNA simply copied information from DNA. What our field discovered was that RNA itself can be modified and edited. The protein we study, called ADAR, modifies RNA to help the cell distinguish between its own RNA and foreign RNA from viruses or bacteria. This is essential because cells constantly encounter bacterial and viral RNA, and they need a way to recognise what belongs to the body and what could be dangerous.</p><p>Our cells modify their own RNA to mark it as “self”. Without these changes, the immune system may mistake the body’s own RNA for a pathogen and launch an immune response against itself. Often, this immune reaction is more dangerous than the infection itself.</p><p>So, RNA modification is not just a small molecular detail –&nbsp;it is essential for survival.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Jdi_do_toho_i_kdyz_ti_rozum_rika_ne_U_kavy_s_Mary_Anne_O_Connell_4_effd6e4b30.jpeg" alt="CEITEC/Martin Indruch: Walk on Air Against Your Better Judgment. Over Coffee with Mary Anne O’Connell: Dragana Vukić and Mary A. O’Connell" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Jdi_do_toho_i_kdyz_ti_rozum_rika_ne_U_kavy_s_Mary_Anne_O_Connell_4_effd6e4b30.jpeg 235w," sizes="100vw" width="1600" height="1067"></p><h5><strong>How has the understanding of RNA changed over the course of your career?</strong></h5><p>Completely.</p><p>When I began, RNA was viewed mainly as a messenger between DNA and proteins. Today it is at the centre of biology and medicine. RNA vaccines changed public awareness of the field, but RNA also influences immunity, inflammation, development, and many diseases. Every few years the field reveals something unexpected. This is also why so many companies are now developing RNA-based therapies, particularly for cancer, where they could help the immune system recognise and fight tumour cells more effectively.</p><h5><strong>You believe RNA-based therapies could change cancer treatment in the future?</strong></h5><p>Yes, I genuinely believe they will.</p><p>The idea is elegant: you sequence a patient’s tumour, identify what makes it unique, and design an RNA-based therapy that trains the immune system to recognise those tumour-specific markers. Of course, this does not mean there will one day be a single universal cure for cancer. Cancer is extremely diverse, with many different forms and mechanisms. But personalised RNA-based therapies have enormous potential because they can be tailored to the specific features of an individual tumour. In the future, treatment could become much more systematic –&nbsp;doctors may one day analyse the tumour sequence and select the most effective therapy from a kind of catalogue of targeted RNA-based treatments.</p><p>And none of this would exist without basic research. The discoveries that later change medicine usually begin as curiosity-driven science.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Jdi_do_toho_i_kdyz_ti_rozum_rika_ne_U_kavy_s_Mary_Anne_O_Connell_5_b691b699f0.jpeg" alt="CEITEC/Martin Indruch: Walk on Air Against Your Better Judgment. Over Coffee with Mary Anne O’Connell: Martin Bareš and  Mary A. O’Connell" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Jdi_do_toho_i_kdyz_ti_rozum_rika_ne_U_kavy_s_Mary_Anne_O_Connell_5_b691b699f0.jpeg 235w," sizes="100vw" width="1600" height="1067"></p><h5><strong>What brought you to CEITEC Masaryk University in Brno?</strong></h5><p>At the time, I was working at the <strong>Medical Research Council in the UK</strong>. Our research funding was cut just before the RNA modification field exploded. We lost funding by a single point in the evaluation of our future proposed projects. We proposed to investigate other types of RNA modification in the 3’UTRs of RNA and to determine how ADAR1 was essential for innate immunity.&nbsp; These are now two major research areas.</p><p>That experience taught me what “cutting-edge science” really means. People love that phrase, but they often forget what it really means. If you are at the cutting edge and funding suddenly contracts, you are the first to be cut off.</p><p>Then the <strong>ERA Chair position at CEITEC</strong> opened. I applied, got the position, and arrived in Brno just as both of these research fields were becoming ‘hot’. Scientifically, the timing to move here could not have been better.</p><h5><strong>What do you like most about Brno?</strong></h5><p>I really love living here. Brno has changed enormously during the ten years I’ve lived here. When I first arrived, you barely heard English on the tram. Now you hear many languages everywhere. It has become much more international and cosmopolitan, but it still feels manageable and human.</p><p>I also think the city has become more self-confident. Earlier, people constantly compared Brno to Prague. Now it feels more comfortable being itself. And honestly, the quality of life here is very good.</p><p>My only real complaint is the airport. But, the cost of living is lower than in many Western European cities, the city centre is beautiful, and you are geographically in the middle of Europe.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Jdi_do_toho_i_kdyz_ti_rozum_rika_ne_U_kavy_s_Mary_Anne_O_Connell_2_efac69f5f7.jpeg" alt="CEITEC: Walk on Air Against Your Better Judgment. Over Coffee with Mary Anne O’Connell: Pavel Plevka, Mary A. O’Connell and Liam Keegan" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Jdi_do_toho_i_kdyz_ti_rozum_rika_ne_U_kavy_s_Mary_Anne_O_Connell_2_efac69f5f7.jpeg 117w," sizes="100vw" width="1600" height="2133"></p><h5><strong>What have you learned about leading a research group?</strong></h5><p>Nobody teaches you how to lead people. I was lucky because I started with a small research group and gradually learned how to manage people over time. I actually think it can be difficult when scientists that are just starting suddenly have large groups, because managing people is a completely different skill from doing science itself.</p><p>What has changed enormously over the years is the level of anxiety and stress among younger researchers. I suspect social media plays a role. People constantly compare themselves to unrealistic versions of other people’s lives and careers and feel pressure to succeed in every aspect of life at once. My generation did not have this pressure.</p><p>When people struggle personally, it immediately affects their research because they cannot think clearly or focus properly. As a group leader, you are no longer only supervising science –&nbsp;you are also trying to support people emotionally. Over the years, I’ve also learned that you cannot solve everything for everyone. Some people accept help and advice, and some do not. That can be difficult, but it is part of leadership too and you have to accept it.</p><h5><strong>In connection with the International Day of Women and Girls in Science, you mentioned resilience as something women bring to science. Can you expand on that?</strong></h5><p>Resilience is essential in science. Experiments fail. Funding disappears. Papers get rejected. Personal situations become complicated. You cannot survive in research without resilience.</p><p>I think many women place enormous pressure on themselves. They compare themselves to impossible standards and feel they are failing. You have to accept that life moves in phases. During difficult periods, you simply keep going.</p><h5><strong>What was the most challenging period in your career?</strong></h5><p>Probably after we lost our funding in the UK. My children were teenagers at the time, and I moved to Sweden for work before eventually coming to Brno. I spent years travelling back and forth every second weekend. Scientifically, the work was worth it. Personally, I missed years of my children growing up.</p><p>That’s one of the difficult realities of science: decisions that are scientifically right can still be personally painful.</p><p>At the same time, that period also taught me a lot about people and kindness. I have always been amazed by the random kindness of strangers. People whom I expected to help me often did not. Meanwhile, people to whom I had simply been kind –&nbsp;without expecting anything in return –&nbsp;were often the ones who helped me most, later in life. My advice is to be kind to everyone, don’t expect people to reciprocate, but that your kindness to others will comes back in unexpected ways.</p><h5><strong>Finally, what advice would you give to your younger self?</strong></h5><p>There is a quote by the Irish poet Seamus Heaney that I love: “Walk on air against your better judgment.” To me, it means: just go for it.</p><p>You only have one life. Try things. Take risks. Sometimes the irrational decisions become the most important ones you ever make.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Jdi_do_toho_i_kdyz_ti_rozum_rika_ne_U_kavy_s_Mary_Anne_O_Connell_98b2e8902f.jpeg" alt="CEITEC: Walk on Air Against Your Better Judgment. Over Coffee with Mary Anne O’Connell: Mary Anne O’Connell" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Jdi_do_toho_i_kdyz_ti_rozum_rika_ne_U_kavy_s_Mary_Anne_O_Connell_98b2e8902f.jpeg 118w," sizes="100vw" width="1600" height="2124"></p>

Walk on Air Against Your Better Judgment. Over Coffee with Mary Anne O’Connell 

<p><strong>If you work in environmental testing, sample preparation, or laboratory instrumentation, you already know that </strong><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/the-importance-of-detecting-per-and-polyfluoroalkyl-substances-pfas"><strong>PFAS (per- and polyfluoroalkyl substances) </strong></a><strong>have become one of the most talked-about topics in the analytical science community. What you may not have seen yet is that in February 2026, the United Kingdom took a landmark step by publishing its very first national framework to address these persistent compounds. It is worth paying attention to, regardless of where your lab operates.</strong></p><h3><strong>What Are 'Forever Chemicals,' and Why the Urgency?</strong></h3><p>PFAS are a group of thousands of synthetic chemicals used in everything from food packaging and cookware to waterproof clothing and firefighting foam. Their defining characteristic is stubborn persistence — they do not readily break down in the environment or in the human body, which is precisely how they earned the "forever chemicals" nickname. Chronic exposure, even at low levels, has been linked to liver damage, high cholesterol, reduced immune responses, and certain cancers.</p><p>The scale of the problem is difficult to overstate. Traces of PFAS have been detected everywhere from the Arctic to Antarctica. Contamination crises have made headlines in Belgium, the United States, and elsewhere. And while regulatory action has been building globally for years — with several U.S. states implementing bans on PFAS in cosmetics beginning in 2025 and the EU <strong>tightening </strong>drinking water protections in January 2026 — the UK had not yet put forward a comprehensive national strategy. Until now.</p><h3><strong>What the UK's PFAS Plan Actually Contains</strong></h3><p>Released on February 3, 2026, the UK government's PFAS Plan is built around three pillars: understanding where PFAS come from, addressing the pathways through which they spread, and reducing ongoing exposure. The framework calls for coordinated action across government agencies, regulators, businesses, and local communities.</p><p><strong>Some of the specific measures outlined include:</strong></p><ul><li>Conducting the first-ever full assessment of PFAS in England's estuaries and coastal waters</li><li>Launching a public consultation on introducing a statutory limit for PFAS in England's public drinking water supply regulations</li><li>Testing food packaging such as microwave popcorn bags and pizza boxes for PFAS presence</li><li>Issuing new guidance to reduce industrial emissions of PFAS</li><li>Expanding soil monitoring in partnership with the British Geological Survey</li><li>Considering restrictions on PFAS in firefighting foams, following ongoing consultation</li></ul><h3><strong>Launching a public-facing website to improve transparency and awareness</strong></h3><p>It is a broad agenda — and not without its critics. Some environmental scientists have pointed out that the plan focuses heavily on monitoring and understanding, with less emphasis on binding phase-out timelines. One researcher noted that legacy contamination sources like <strong>landfill sites </strong>may actually be releasing more PFAS into rivers than current industrial activity, and that simply measuring concentrations falls short of tracking the total amount being discharged. Unlike France, which became the first EU country to fully ban PFAS in cosmetics, the UK is not currently pursuing an outright ban.</p><p>Supporters, meanwhile, have acknowledged it as a meaningful first step — particularly given the complexity of the PFAS challenge. There is not even universal agreement on <strong>what counts as a PFAS compound</strong>; depending on the definition used, the group could include anywhere from under five thousand to over seven million potential substances.</p><h3><strong>Why This Is Relevant to the Laboratory World</strong></h3><p>Here is where I want to bring this closer to home for those of us in the analytical instrumentation and sample preparation space.</p><p>The push to understand and regulate PFAS at the scale the UK is now proposing means one thing clearly: demand for <strong>rigorous PFAS testing</strong> is going to grow. Every assessment of estuaries, every soil sampling initiative, every test on food packaging generates samples that need to be analyzed. And PFAS analysis is not straightforward.</p><p>Current <strong>USEPA-published analytical methods for PFAS </strong>rely primarily on liquid chromatography-tandem mass spectrometry (<a target="_blank" rel="noopener noreferrer" href="https://www.organomation.com/preparing-samples-for-lc-ms/ms-analysis"><strong>LC-MS/MS</strong></a>). Proper sample preparation is critical to producing reliable results, especially since PFAS often appear at trace concentrations and can be easily introduced as contaminants during the preparation process itself. Solid-phase extraction (<a target="_blank" rel="noopener noreferrer" href="https://www.organomation.com/what-is-solid-phase-extraction-spe"><strong>SPE</strong></a>) is a widely used technique for isolating PFAS from complex matrices like water and soil, but effective concentration of samples before analysis is equally important — and that is exactly where evaporative concentration instruments become indispensable in the workflow.</p><p>At Organomation, our evaporators are used in PFAS sample preparation workflows aligned with <strong>EPA Methods 533, 537.1, and 1633 </strong>— the key analytical methods used for PFAS in drinking water, environmental water, and a broad range of solid matrices including soil, biosolids, and tissue. These methods require careful, controlled solvent evaporation to concentrate samples without loss of target analytes or introduction of contamination. Getting this step right is not optional — it directly determines the accuracy and reliability of the final result.</p><h3><strong>A Global Challenge That Demands a Global Scientific Response</strong></h3><p>The UK's PFAS Plan is one piece of what is becoming a coordinated international effort. The Stockholm Convention on Persistent Organic Pollutants added<strong> long-chain perfluorocarboxylic acids</strong> (over 200 additional PFAS substances) to its global elimination list in May 2025. The EU introduced mandatory PFAS monitoring requirements for drinking water in January 2026. And in the United States, regulatory pressure at both federal and state levels continues to tighten.</p><p>What all of this regulatory momentum signals is that the window for labs to build PFAS testing capability is not narrowing — it is widening. Governments are committing to monitoring. Industries are being pushed toward safer alternatives. And at every step of that process, someone needs to run the samples.</p><p>Whether you are setting up a new <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products?manufacturerItems=540&amp;search=Free"><strong>PFAS testing workflow </strong></a>or scaling up an existing one, the fundamentals of good sample preparation have not changed: control your contamination sources, use validated methods, and make sure your<strong> concentration step</strong> is working properly. The regulatory environment is evolving quickly, but sound science is the constant.</p><p>I am proud that Organomation's instruments continue to play a role in the analytical workflows that make this kind of environmental accountability possible. As governments around the world sharpen their focus on PFAS, the laboratory community will be at the center of that work.</p>

The UK Just Released Its First-Ever Plan to Tackle 'Forever Chemicals' — Here's Why It Matters for Labs

<p><strong>Our Library never stops expanding. What are the most recent contributions to LabRulezLCMS Library in the week of 13th July 2026? Check out new documents from the field of liquid phase, especially HPLC and LC/MS techniques!</strong></p><blockquote><p><span style="font-size:20px;">👉 </span><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library"><span style="font-size:20px;"><strong>SEARCH THE LARGEST REPOSITORY OF DOCUMENTS ABOUT LCMS AND RELATED TECHNIQUES</strong></span></a></p></blockquote><blockquote><p><strong>👉 Need info about different analytical techniques?</strong> Peek into <a target="_blank" rel="noopener noreferrer" href="https://gcms.labrulez.com/library"><strong>LabRulezGCMS</strong></a> or <a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/library"><strong>LabRulezICPMS</strong></a> libraries.</p></blockquote><p>This week we bring you posters by <strong>Agilent Technologies / ASMS, Shimadzu / ASMS, Thermo Fisher Scientific / HPLC Symposium </strong>and<strong> Waters Corporation / HPLC Symposium </strong>and technical note by<strong> KNAUER!</strong></p><h3><strong>1. Agilent Technologies / ASMS: Intact Protein Analysis in Plasma Using Automated 2D-LC/TOF with Multiple Heart-Cutting</strong></h3><ul><li>Poster</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/po_intact_protein_mhc_2d_lc_tof_wp_679_asms_2026_en_agilent_edb54f4854.pdf"><strong>Full PDF for download</strong></a></li></ul><p>Direct intact and top-down protein analysis enables comprehensive characterization of proteoforms, post-translational modifications, and fragments that are often lost in bottom-up workflows.1 However, intact mass analysis in complex biological matrices such as whole plasma is challenged by extreme dynamic range and ion suppression, commonly necessitating affinity-based enrichment.&nbsp;</p><p>Here, we demonstrate a non-affinity, orthogonal separation strategy using a 2D-LC/TOF workflow with multi-heart-cutting for native intact protein analysis directly in plasma. Therapeutic monoclonal antibodies (mAbs) trastuzumab and antibody-drug conjugate T-DM1, were used as model systems to evaluate performance.&nbsp;</p><p>The workflow employs an Agilent 1290 Infinity III 2D-LC system for orthogonal separations and precise multiple heart-cutting, coupled to a high-resolution, high-sensitivity Agilent 6230C Accurate Mass TOF LC/MS System.</p><h4><strong>Experimental</strong></h4><h5><strong>Instrumentation&nbsp;</strong></h5><ul><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=1290+Infinity+III+2D-LC"><strong>Agilent 1290 Infinity III 2D-LC system </strong></a>comprised the following modules:&nbsp;<ul><li>1290 Infinity III Bio Multisampler with Thermostat (G7137A)&nbsp;</li><li>1290 Infinity III Multicolumn Thermostat (G7116B)&nbsp;</li><li>1290 Infinity III Diode Array Detector (G7117B) with Max-Light cartridge cell (G7117-60020)&nbsp;</li><li>1260 Infinity III Bio Flexible Pump (G7131C)&nbsp;</li><li>1290 Infinity III Bio High-speed Pump (G7132A)&nbsp;</li><li>1290 Infinity Valve Drive (G1170A) with 2D-LC ASM Valve (G5643B)&nbsp;</li><li>Two 1290 Infinity III Valve Drives (G1170A) with multiple heart-cutting valves (G5642-64000) equipped with 40 µL Bio loops&nbsp;</li><li>1290 Infinity III Valve Drive (G1170A) with a 2- position/6-port valve (G4231A) (used as a diverter valve)&nbsp;</li></ul></li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=6230C"><strong>Agilent 6230C Accurate Mass TOF LC/MS System</strong></a></li></ul><h5><strong>LC/MS Analysis&nbsp;</strong></h5><p>Data acquisition and analysis were carried out using <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=MassHunter+acquisition"><strong>MassHunter acquisition</strong></a> (12.2), <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=BioConfirm"><strong>BioConfirm</strong></a> (12.1) and <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=10&amp;search=MassHunter+Qualitative+Analysis"><strong>MassHunter Qualitative Analysis </strong></a>(13.0) software.</p><h4><strong>Conclusions</strong></h4><ul><li>Agilent 2D-LC enables direct native MS analysis of intact proteins from plasma without affinity-based enrichment.&nbsp;</li><li>UV-guided and multiple heart-cutting simplify 2D-LC method development and provide high-resolution isolation of native proteins from complex biological matrices such as plasma.&nbsp;</li><li>The Agilent 6230C Accurate Mass TOF delivers high sensitivity and excellent mass accuracy, enabling confident intact protein characterization under native conditions.</li></ul><h3><strong>2. KNAUER: Mind the pressure in preparative up-scaling – effects of particle size and solvent composition on back pressure</strong></h3><ul><li>Technical note</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/VTN_0051_knauer_mind_the_pressure_in_preparative_up_scaling_effects_of_particle_size_and_solvent_comp_12e49884d3.pdf"><strong>Full PDF for download</strong></a></li></ul><p>The back pressure of a chromatographic system is generated by the system components, the capillaries, the column, the solvent, and the applied flow rate. Each system has a maximum pressure which it can sustain, and therefore the pressure must be monitored as it is a limiting factor during method development. The back pressure generated by a column is dependent on the particle size and its length. The development of a preparative method is ideally performed on an analytical scale and after optimization the method is then scaled up to preparative scale.</p><p>As preparative HPLC systems normally have lower maximum pressures, it is important to keep the generated pressure in the range of the later preparative system.&nbsp;</p><p>The larger the particles of the column material are, the lower will be the generated back pressure. With increasing particle size, the resolution is decreasing at the same time. Depending on the separation task, the resolution can be a critical point, and it is important to find the right compromise between resolution and backpressure. Additionally, larger particles are significantly less price intensive, which is another factor to be considered especially for large scale purifications. Often solvent mixtures of water with acetonitrile, methanol or ethanol are used for reverse phased methods. Depending on the organic solvent composition, the generated back pressure differs significantly which could be reduced by changing the solvent composition slightly or the organic solvent if possible. The back pressure generated by the solvent will not or only slightly change during the up-scaling process.&nbsp;</p><p>Here, the influence of particle size, flow rate and solvent composition on the back pressure was evaluated. Further, a practical scale-up was performed to evaluate the values obtained on analytical scale to those in larger scale.</p><h4><strong>User Tips:&nbsp;</strong></h4><ul><li>What is the finale scale you want to operate later?&nbsp;</li><li>What are the pressure limitations of the preparative system?&nbsp;</li><li>Be aware of the solvent back pressure&nbsp;</li><li>Consider particle size not only for best separation&nbsp;</li><li>Consider the flow rate</li></ul><h4><strong>MATERIAL AND METHODS&nbsp;</strong></h4><ul><li><strong>Pump: </strong><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2372"><strong>AZURA® P 6.1LHPG</strong></a>, 10 ml, sst&nbsp;</li><li><strong>Autosampler: </strong><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2375"><strong>AZURA AS 6.1L</strong></a></li><li><strong>Detector:</strong> <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2423"><strong>UV AZURA DAD 2.1L&nbsp;</strong></a></li><li><strong>Flow cell: </strong>Pressure proof 10 mm, 10 µl, 300 bar&nbsp;</li><li><strong>Thermostat:</strong> <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2376"><strong>CT2.1&nbsp;</strong></a></li><li><strong>Columns:&nbsp;</strong><ul><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1633"><strong>Eurospher II 100-5 C18, 150 x 4.6 mm&nbsp;</strong></a></li><li>Eurospher II 100-10 C18, 150 x 4.6 mm&nbsp;</li><li>Eurospher II 100-15 C18, 150 x 4.6 mm&nbsp;</li><li>Eurospher II 100-20/45 C18, 150 x 4.6 mm &nbsp;</li></ul></li><li><strong>Software&nbsp;</strong><ul><li>ClarityChrom 10.1&nbsp;</li><li>ClarityChrom 10.1 PDA extension</li></ul></li></ul><h4><strong>CONCLUSION&nbsp;</strong></h4><p>The back pressures of four C18 150 x 4.6 mm columns, which differed only in particle size were measured and compared at different flow rates and solvent compositions. As expected, the 5 µm column showed the highest and the 20/45 µm column the lowest back pressure at all tested conditions. The pressure curves of ethanol and methanol gradients were similar, with a maximum pressure at approximately 50% solvent. The pressure curve of the acetonitrile gradient differed from the other two, showing the highest pressure at a lower organic solvent content of approximately 35%, after which the pressure dropped. Ethanol showed the highest pressure, followed by methanol and then acetonitrile. Determining the column back pressure at an analytical scale is an important tool during preparative method development. Ideally, if a linear scale up from the analytical to the preparative scale is conducted, the column back pressure should stay the same. This helps to predict if the method can be scaled up to the desired size in terms of back pressure.</p><h3><strong>3. Shimadzu / ASMS: Enhanced Quantification of Emerging UV Filter Contaminants in Drinking Water Using Optimized LC-MS/MS Technique</strong></h3><ul><li>Poster</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/TP_121_Enhanced_Quantification_of_Emerging_UV_Filter_Contaminants_in_Drinking_Water_Using_Optimized_LC_MSMS_Technique_e733c64828.pdf"><strong>Full PDF for download</strong></a></li></ul><p>Ultraviolet (UV) filter chemicals from sunscreens and personal care products are increasingly recognized as emerging contaminants of concern in drinking water1 . Their persistence and reported biological effects highlight the need for sensitive and reliable monitoring approaches2 . The objectives were to optimize quantitation to achieve ppt level detection without offline extraction and assess the occurrence of these compounds in multiple drinking water matrices. In this study, 20 UV filters were analyzed using a <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=1&amp;search=LCMS-8060RX"><strong>Shimadzu LCMS8060RX triple quadrupole mass spectrometer.</strong></a></p><h4><strong>Conclusion</strong></h4><p>A highly sensitive, precise, and robust direct injection LC–MS/MS method enables sub-ppt to high-ppb quantification of 20 UV filters in drinking water. Overall, the highly sensitive and robust Shimadzu LCMS-8060RX Triple Quadrupole Mass Spectrometer combined with this extraction-free workflow provides a simple, reliable, and high-throughput approach for quantifying emerging UV filters at ng/L concentrations in drinking water.</p><h3><strong>4. Thermo Fisher Scientific / HPLC Symposium: Comparison of biocompatible and inert UHPLC systems for LC-UV quantitation of large RNA</strong></h3><ul><li>Poster</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/po_004752_hplc_vanquish_amplify_metal_sensitive_analyte_analysis_po004752_na_en_ff99cfde49.pdf"><strong>Full PDF for download</strong></a></li></ul><p>Accurate LC-UV analysis of large RNA and oligonucleotide therapeutics requires highly inert chromatographic flow paths because interactions between the negatively charged phosphodiester backbone and metallic surfaces can cause analyte loss, peak broadening, and reduced quantitative sensitivity, particularly at low concentration.&nbsp;</p><p>Here, an inert UHPLC system – Vanquish Amplify system, incorporating inert-coated flow path components was evaluated against a biocompatible UHPLC configuration using MP35N alloy capillaries and additionally against a commercially available inert UHPLC platform. Large RNA fragments of 500 and 5000 nucleotides were analyzed by IP-RPLC to assess the difference between these systems. To further investigate flow path interactions, adenosine 5′- (α,β-methylene) diphosphate (AMPcP), a metal-sensitive analyte, was analyzed alongside adenosine, a noninteracting reference compound.</p><h5><strong>Material and Methods</strong></h5><ul><li><strong>Instrumentation: </strong>Thermo Scientific Vanquish Amplify UHPLC system</li><li><strong>Column:</strong> <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=3&amp;search=SurePac+Oligo"><strong>Thermo Scientific SurePac Oligo RP MDi HPLC column</strong></a>,<br>2.5 µm 2.1 X 50 mm (P/N: 43712-052132</li><li><strong>Data Analysis: </strong><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/76"><strong>The Thermo Scientific Chromeleon Software 7.3.2 MUc Chromatography Data System (CDS)</strong></a> was used for all data acquisition and analysis.</li></ul><h4><strong>Conclusions&nbsp;</strong></h4><p>Using AMPcP with the Vanquish Amplify system demonstrated up to a twofold increase in sensitivity compared to systems with MP35N fluidics under conditions where metal interactions are most pronounced&nbsp;</p><p>For large RNA, the Vanquish Amplify UHPLC system delivered 1.25–1.35× higher signal intensity compared to systems with MP35N fluidics, enabling reduced sample consumption and improved quantitative reliability.&nbsp;</p><p>The Vanquish Amplify UHPLC system demonstrated comparable system inertness under the tested conditions for larger RNA fragments (5,000 nt) and slightly better system inertness for smaller fragments (500 nt) in this study than the MaxPeak HPS containing system, based on peak height and area comparisons using an external UV detector</p><h3><strong>5. Waters Corporation / HPLC Symposium: Development and Transfer of Quantitative Analytical Methods using Universal Detectors</strong></h3><ul><li>Poster</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/720009493_8cbe4c3cc2.pdf"><strong>Full PDF for download</strong></a></li></ul><div><div><section><div><div><div><div><div><div><p>Universal detectors such as <strong>Charged Aerosol Detection (CAD)</strong> and <strong>Evaporative Light Scattering Detection (ELSD)</strong> provide valuable alternatives to traditional LC detectors including UV, fluorescence, and mass spectrometry, particularly for analytes lacking chromophores. Although both detectors are suitable for quantitative analysis, they rely on different detection principles—CAD measures the electrical charge transferred to aerosol particles, whereas ELSD detects light scattered by dried analyte particles. Because both detectors exhibit non-linear responses, quantitative methods typically require calibration models such as log-log linear or quadratic regression rather than conventional linear calibration. The poster discusses key considerations for developing robust quantitative methods and highlights the challenges associated with transferring methods between different universal detection platforms.</p><p>To demonstrate detector transferability, the authors migrated a <strong>HILIC method for sugar analysis in fruit juice</strong> from ELSD to CAD. The separation was performed on a <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/306"><strong>Waters Arc HPLC System</strong></a> equipped with an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=5&amp;search=XBridge+BEH+Amide"><strong>XBridge BEH Amide</strong></a><strong> (4.6 × 150 mm, 2.5 μm)</strong> column using a water/acetonitrile gradient containing triethylamine. While the chromatographic conditions remained unchanged, CAD detector parameters were optimized. Both detectors produced highly comparable quantitative performance across a calibration range of <strong>50–1000 μg/mL</strong>, achieving calibration coefficients (R²) above <strong>0.995</strong>, area RSD values below <strong>1.5%</strong>, and nearly identical concentrations of fructose, sorbitol, glucose, and sucrose in an apple juice sample. These results demonstrate that quantitative HILIC methods can be successfully transferred between ELSD and CAD with only detector-specific optimization.</p><p>The poster also evaluates method transfer between different CAD platforms using the <strong>USP Deoxycholic Acid assay</strong>. The method was implemented on a <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/198"><strong>Waters ACQUITY UPLC H-Class PLUS System</strong></a> with an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1823"><strong>XBridge BEH C18</strong></a><strong> (4.6 × 150 mm, 3.5 μm)</strong> column and compared against a competing LC/CAD system. After scaling the method according to <strong>USP Chapter &lt;621&gt;</strong>, both systems met all USP system suitability requirements, including repeatability and signal-to-noise criteria. Quantitative results for deoxycholic acid and related impurities were virtually identical, confirming that validated CAD methods can be reliably transferred between different vendors' LC/CAD platforms without compromising analytical performance.</p><p>Overall, the study demonstrates that both ELSD and CAD are robust universal detection techniques for quantitative liquid chromatography. While method transfer between identical detector types is generally straightforward, successful migration between ELSD and CAD—or between different CAD systems—requires careful optimization of detector parameters while preserving chromatographic conditions. The presented workflows illustrate that with appropriate calibration and detector tuning, laboratories can achieve equivalent sensitivity, precision, and quantitative accuracy, facilitating method standardization and transfer across analytical platforms.</p></div></div></div></div></div></div></section></div></div>

News from LabRulezLCMS Library - Week 29, 2026

Article

Scientists

Environment

Poster

Since its establishment in 2011, CEITEC has quickly developed into a cutting-edge infrastructure for research which performs highly alongside the best institutes in Europe. Among the main priorities of CEITEC are the promotion of a motivating and dynamic international scientific environment, the provision of state-of-the-art research infrastructure, and the policy of open communication and equal opportunities.

CEITEC

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Agilent Technologies

Shimadzu Corporation

Evosep Biosystems

Waters Corporation

<p><strong>It takes time, money, and resources to generate laboratory data, so any loss of data is a direct financial loss to your regulated company, as well as a major compliance risk.  Laboratory data must be secured and available to support product quality decisions, both at the time of decision making and for the full duration of the mandated retention period.</strong></p>
<p>A regulated company must ensure its data is retained through the retention period and maintains its integrity during that time.  While external assistance can be sought with activities such as backup and restore, disaster recovery and business continuity planning, archiving, system administration and cybersecurity, the overall responsibility for the regulated data remains with the regulated company.</p>
<p>Key points of discussion will be:</p>
<ol>
<li><strong>Working with Servers</strong></li>
<li><strong>Having a Backup and Restore Plan</strong></li>
<li><strong>Developing a Disaster Recovery Plan</strong></li>
<li><strong>Have a Business Continuity Plan</strong></li>
<li><strong>Archiving Data</strong></li>
<li><strong>Cybersecurity Considerations</strong></li>
<li><strong>Updates to Software</strong></li>
</ol>
<p>Please join us for a live discussion as we explore this topic.  As always, don’t forget to bring your Empower questions for this exclusive opportunity to ask our experts anything about Empower Software.</p>
<blockquote>
<p><strong>Presenter:</strong> Neil Lander (Principal Product Manager, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Neil has worked for Waters Corporation since 1994 and has held a variety of positions including Technical Support Specialist, Technical Trainer, Manager Customer Education and currently, Principal Marketing Manager focusing on Informatics solutions. He provides internal support for Empower Chromatography Data System and is focused on developing laboratory software solutions that help organizations achieve their scientific and operational objectives. Prior to joining Waters, he was an analytical chemist where he gained experience in both the cosmetics and specialty chemical industries.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Fiona O&#39;Leary (Informatics Consultant, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Fiona is an experienced Empower Software and Data Integrity professional working within the EU Professional Services Team.</p>
</blockquote>
<blockquote>
<p>She has ~18 years of experience with Waters, beginning with Technical Support &amp; Empower Training, moving to Empower Consultancy and Workflow Optimization in more recent years. Her focus now is on building Data Integrity into the Lab workflow, Custom Field automation and Electronic Data Review / Reporting optimization.</p>
</blockquote>
<blockquote>
<p>Prior to joining Waters, Fiona spent some years in the GxP Pharmaceutical Manufacturing world, setting the scene for her current goal of helping organizations achieve their scientific and operational objectives efficiently and within compliance guidelines. She graduated from Dublin City University in 2001 with a BSc Hons. Analytical Science.</p>
</blockquote>


Waters Corporation: A Guide to Ensuring Your Data Is Secure and Available from Creation Thru the Full Mandated Retention Period

A Guide to Ensuring Your Data Is Secure and Available from Creation Thru the Full Mandated Retention Period

As always, don’t forget to bring your Empower questions for this exclusive opportunity to ask our experts anything about Empower Software.

Ensuring Your Data Is Secure and Available

<p><strong>Biological samples represent formidable challenges in sample preparation that hold important consequences for LC analysis. Cleaner samples translate to more robust, reproducible LC analysis, with fewer repeat runs, and less equipment down time. The challenge is knowing which sample preparation technique to combine with both your sample and LC method.</strong></p>
<p>In this discussion we will look at some common bio sample preparation techniques, from solvent exchanges to solid phase extractions. We will then discuss how to match the sample preparation technique to both your sample and the desired outcome of your chromatography.</p>
<blockquote>
<p><strong>Presenter:</strong> Melissa Goodlad (Application Engineer, Agilent Technologies, Inc.)</p>
</blockquote>
<blockquote>
<p>Melissa Goodlad is an Application Engineer providing applications assistance and technical support for Agilent’s HPLC columns and consumables. Before joining Agilent, Melissa was completing her PhD in Physical Chemistry at UC Merced studying nanoparticle self-assemblies.</p>
</blockquote>


Agilent Technologies: Sample Preparation for Improved LC Bio Separations

Sample Preparation for Improved LC Bio Separations

In this discussion we will look at some common bio sample preparation techniques, from solvent exchanges to solid phase extractions.

<p><strong>When it comes to LC analysis, a common question for users is, “Which LC column should I choose?” The column is the heart of the LC system, which plays a pivotal role in ensuring high-resolution separation. The fundamental knowledge of column selection can hence help you decide the optimal column for your specific application.</strong></p>
<p>In this second series of Understanding LC Columns webinar, we will introduce the different mode of separation in liquid chromatography including reversed phase, normal phase and HILIC. We will discuss some of the common applications for each of these separation techniques. The difference in column chemistry and column specifications can significantly impact your separation. This webinar will also cover the different column chemistry and the considerations when selecting a column for the different applications.</p>
<p>Learning Objectives</p>
<ul>
<li><strong>Understand the different mode of separation and their application in liquid chromatography.</strong></li>
<li><strong>Understand the different column chemistry and their separation mechanisms.</strong></li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Dr. Derrick Tan (Application Chemist (Consumables), Shimadzu (Asia Pacific) Pte Ltd)</p>
</blockquote>
<blockquote>
<p>Dr. Derrick Tan obtained his PhD in chemistry from Nanyang Technological University, Singapore. He has more than 7 years of research experience in small molecules, nucleic acids, peptides and protein synthesis, separation and purification. He joined Shimadzu (Asia Pacific) Pte Ltd in 2021 as an Application Chemist (Consumables). At Shimadzu, he is responsible for the technical support and application of consumables in chromatography and spectroscopy. Products include LC and GC columns, UV/Vis cuvettes, sample vials and accessories.</p>
</blockquote>


Shimadzu: Understanding LC Columns - Difference in Column Types and Phases

Understanding LC Columns - Difference in Column Types and Phases

We will introduce the different mode of separation in liquid chromatography including reversed phase, normal phase and HILIC.

Understanding LC Columns - Column Types and Phases

<p><strong>In UV-VIS-NIR spectroscopy, there is a wide range of instruments available that cover all measurements from routine to research.</strong></p>
<p>We will discuss in this presentation some of the key performance differentiators between spectrometers as well as the impact that these have on measurement capabilities.</p>
<blockquote>
<p><strong>Presenter:</strong> Scott Melis, PhD (Application Scientist, Agilent Technologies, Inc.)</p>
</blockquote>
<blockquote>
<p>Scott Melis has a PHD in Physics from Georgetown University in Washington, DC and started with Agilent in 2021 as a Molecular Spectroscopy Application Scientist. In his graduate work, Scott studied nanoparticle formation and growth for a variety of applications. Projects that he worked with include developing processes to deposit and characterize semiconducting molecular nano-cocrystals for use in optoelectronic devices as well as controlling polymer nanoparticle size through rapid mixing conditions.</p>
</blockquote>


Agilent Technologies: Picking the Right UV-Vis-NIR For Me: What Specs Do I Need?

Picking the Right UV-Vis-NIR For Me: What Specs Do I Need?

Key performance differentiators between UV-VIS-NIR spectrometers as well as the impact that these have on measurement capabilities.

<p><strong>How do I collect a UV-VIS Baseline?  Why is my concentration curve non-linear?  What amount of averaging do I need to do?</strong></p>
<p>Join us in this webinar where we will discuss some of the most common questions for UV-VIS data collection.</p>
<blockquote>
<p><strong>Presenter:</strong> Scott Melis, PhD (Application Scientist, gilent Technologies, Inc.)</p>
</blockquote>
<blockquote>
<p>Scott Melis has a PHD in Physics from Georgetown University in Washington, DC and started with Agilent in 2021 as a Molecular Spectroscopy Application Scientist. In his graduate work, Scott studied nanoparticle formation and growth for a variety of applications. Projects that he worked with include developing processes to deposit and characterize semiconducting molecular nano-cocrystals for use in optoelectronic devices as well as controlling polymer nanoparticle size through rapid mixing conditions.</p>
</blockquote>


Agilent Technologies: Common UV-Vis Questions Answered

Common UV-Vis Questions Answered

Join us in this webinar where we will discuss some of the most common questions for UV-VIS data collection.

<p><strong>If you are new to our technology or just getting started this event is for you. We will introduce the basics of the Evosep One technology and include hot-from-the-lab data from our users. Nicolai Bache, Head of Applications at Evosep, will host the event, bringing you up to speed with the latest additions to the Evosep One technology.</strong></p>
<p>The Evosep One is a plug-and-play standardized platform designed for robustness and high throughput. It has been designed specifically to address and eliminate the prevalent challenges associated with throughput and robustness of nano-flow LC-MS workflows while maintaining sufficient sensitivity and resolving power for clinical applications.</p>
<p>The Evosep One technology is centered around the Evotip and integrates sample preparation with LC-MS. The Evotip is essentially a disposable trap column in a pipette tip format with a small plug of C18 stationary phase at the bottom of the tip. The Evotips are used to desalt and clean up the samples prior to LC-MS analysis, however, the traditional subsequent steps of eluting, drying down, re-suspending the samples from tips are completely omitted and instead the tips are loaded directly into Evosep One for analysis.</p>
<p>The system uses four low-pressure syringe pumps in parallel to elute samples from the Evotip with a chromatographic gradient. The resulting gradient with the pre-separated sample is moved into a storage loop, that is then switched in-line with a single high-pressure pump and an analytical separation column for focusing. With this simplified workflow on pre-set gradients, the Evosep One offers a throughput from 30 to 300 samples per day.</p>
<h5><strong>1. A beginner’s guide to the Evosep One</strong></h5>
<ul>
<li>Presenter: Nicolai Bache (Head of applications at Evosep)</li>
</ul>
<p>The Evosep One technology is centered around the Evotip and integrates sample preparation with LC-MS. The Evotip is essentially a disposable trap column in a pipette tip format with a small plug of C18 stationary phase at the bottom of the tip. The Evotips are used to desalt and clean up the samples prior to LC-MS analysis, however, the traditional subsequent steps of eluting, drying down, re-suspending the samples from tips are completely omitted and instead the tips are loaded directly into Evosep One for analysis.</p>
<h5><strong>2. To be announced</strong></h5>
<ul>
<li>Presenter: Anh Reynolds (Associate Scientist at BMS)</li>
</ul>
<h5><strong>3. Clinical proteomics in the fast lane – Combination of robust LC, timsTOF based IMS-MS and GPU powered data processing</strong></h5>
<ul>
<li>Presenter: Allan Stensballe (Industrial PHD at Aalborg University)</li>
</ul>
<p>Mass spectrometrists who have been in the proteomics field long enough to be users of both early gel-free and gel-based strategies have learned to appreciate robust and fast analysis pipelines. As clinical proteomics projects now increasingly moves towards larger cohort studies and integration in multiOmics projects the stability and reproducibility of LC-MS to data analysis is imperative.  In this talk I will highlight our experiences, project examples and thoughts on use of clinically optimized and standardized workflows.</p>


A beginner’s guide to Evosep

The Evosep One is a plug-and-play standardized platform designed for robustness and high throughput.

<p><strong>At the analytical scale, liquid chromatography (LC) is widely used by scientists to separate, quantify, and characterize components in mixtures. At the preparative scale, LC is primarily used to purify samples for further downstream analysis. The adoption of preparative LC into a workflow, with larger columns and instrumentation, can appear to be a daunting task. However, by following some fundamental guidelines and a little practical advice, it can be quite simple.</strong></p>
<h5>Key learning objectives</h5>
<ul>
<li><strong>Become familiar with the analytical to preparative chromatography workflow</strong></li>
<li><strong>Learn strategies to efficiently develop methods for purification success</strong></li>
<li><strong>Know how to avoid or recover from common mistakes</strong></li>
<li><strong>Understand how to think like a purification scientist</strong></li>
</ul>
<h5>Who should attend?</h5>
<ul>
<li>Analytical and medicinal chemists who want to learn more about purification or preparative LC, or regarding scale-up from analytical to preparative LC</li>
<li>Lab managers supporting purification labs</li>
<li>Scientists who are curious about incorporating purification into their laboratory workflow</li>
</ul>
<p> </p>
<blockquote>
<p><strong>Presenter:</strong> Scott Bollen (Business Development Manager EMEA, Agilent Technologies)</p>
</blockquote>
<blockquote>
<p>Scott specializes in small molecule LC columns, ranging from HPLC to UHPLC. Scott has worked at Agilent for 17 years. He started as a technical support manager, and now supports new LC products in R&amp;D as well as the entirety of the existing small molecule LC column portfolio in business development.</p>
</blockquote>


Agilent Technologies: Scale Up from Analytical to Prep with Agilent Prep LC Columns

Scale Up from Analytical to Prep with Agilent Prep LC Columns

Become familiar with the analytical to preparative chromatography workflow and learn strategies to efficiently develop methods for purification success.

From Analytical to Prep with Agilent Prep LC Columns

<p>Join us on 18 &amp; 19 January for two half days of virtual presentations as we help you to navigate the every day challenges faced with the analysis of oligonucleotides. Presented by experts in the industry and the Agilent biopharma team, these short talks are designed to educate and provide insight from basic oligonucleotide assessment, through to the more advanced applications. Q&amp;A sessions will follow each presentation to give you the opportunity to engage with our speakers.</p>
<p>The agenda will cover these topics below and more!</p>
<ul>
<li>Introduction to Oligonucleotide Therapeutics</li>
<li>Analytical &amp; Purification Methods</li>
<li>Workflows for Oligonucleotide CQAs</li>
<li>Practical Tips &amp; Tricks for Preparative HPLC</li>
<li>Analysis of mRNA 5&#39; Capping and Poly-A Tailing by High Resolution LC/MS</li>
</ul>
<h3><strong>Agenda Day 1</strong></h3>
<h5><strong>10:00  Welcome to Agilent Oligo Insight Days</strong></h5>
<h5><strong>10:10  Introduction to Oligonucleotide Therapeutics</strong></h5>
<h5><strong>10:45  Oligonucleotide Analytical and Purification Methods</strong></h5>
<h5><strong>11:25  Workflows for Analysis of Oligonucleotide CQAs</strong></h5>
<h5><strong>12:05  Oligonucleotide Analysis - Tips &amp; Tricks: Putting it all into Practice</strong></h5>


Agilent Technologies: Agilent Oligonucleotide Insight Days

Agilent Oligonucleotide Insight Days (Day 1)

Taking A Deeper Dive into Oligonucleotide Analysis

<p>Join us on 18 &amp; 19 January for two half days of virtual presentations as we help you to navigate the every day challenges faced with the analysis of oligonucleotides. Presented by experts in the industry and the Agilent biopharma team, these short talks are designed to educate and provide insight from basic oligonucleotide assessment, through to the more advanced applications. Q&amp;A sessions will follow each presentation to give you the opportunity to engage with our speakers.</p>
<p>The agenda will cover these topics below and more!</p>
<ul>
<li>Introduction to Oligonucleotide Therapeutics</li>
<li>Analytical &amp; Purification Methods</li>
<li>Workflows for Oligonucleotide CQAs</li>
<li>Practical Tips &amp; Tricks for Preparative HPLC</li>
<li>Analysis of mRNA 5&#39; Capping and Poly-A Tailing by High Resolution LC/MS</li>
</ul>
<h3><strong>Agenda Day 1</strong></h3>
<h5><strong>10:00  Welcome to Agilent Oligo Insight Days</strong></h5>
<h5><strong>10:10  A Beginners Guide to LC/MS for the Analysis of Oligonucleotides</strong></h5>
<h5><strong>10:45  Analysis of mRNA 5&#39; Capping and Poly-A Tailing by High-Resolution LC/MS</strong></h5>
<h5><strong>11:20  Nucleic Acids Therapeutics Delivery by LNPs: Fundamentals and Characterizations</strong></h5>
<h5><strong>12:05  Oligonucleotide Purification - Tips and Tricks How to Scale Up!</strong></h5>


Agilent Oligonucleotide Insight Days (Day 2)

<p><strong>It takes time, money, and resources to generate laboratory data, so any loss of data is a direct financial loss to your regulated company, as well as a major compliance risk. &nbsp;Laboratory data must be secured and available to support product quality decisions, both at the time of decision making and for the full duration of the mandated retention period.</strong></p><p>A regulated company must ensure its data is retained through the retention period and maintains its integrity during that time. &nbsp;While external assistance can be sought with activities such as backup and restore, disaster recovery and business continuity planning, archiving, system administration and cybersecurity, the overall responsibility for the regulated data remains with the regulated company.</p><p><strong>Key points of discussion will be:</strong></p><ul><li>Working with Servers</li><li>Having a Backup and Restore Plan</li><li>Developing a Disaster Recovery Plan</li><li>Have a Business Continuity Plan</li><li>Archiving Data</li><li>Cybersecurity Considerations</li><li>Updates to Software</li></ul><p>Please join us for a live discussion as we explore this topic. &nbsp;As always, don’t forget to bring your Empower questions for this exclusive opportunity to ask our experts anything about Empower Software.</p><blockquote><p><strong>Presenter: </strong>Neil Lander (Principal Product Manager, Informatics, Waters Corporation)</p><p>Neil has worked for Waters Corporation since 1994 and has held a variety of positions including Technical Support Specialist, Technical Trainer, Manager Customer Education and currently, Principal Marketing Manager focusing on Informatics solutions. He provides internal support for Empower Chromatography Data System and is focused on developing laboratory software solutions that help organizations achieve their scientific and operational objectives. Prior to joining Waters, he was an analytical chemist where he gained experience in both the cosmetics and specialty chemical industries.</p><p><strong>Presenter:&nbsp;</strong>Fiona O'Leary (Informatics Consultant, Waters Corporation)</p><p>Fiona is an experienced Empower Software and Data Integrity professional working within the EU Professional Services Team.</p><p>She has ~18 years of experience with Waters, beginning with Technical Support &amp; Empower Training, moving to Empower Consultancy and Workflow Optimization in more recent years. Her focus now is on building Data Integrity into the Lab workflow, Custom Field automation and Electronic Data Review / Reporting optimization. Prior to joining Waters, Fiona spent some years in the GxP Pharmaceutical Manufacturing world, setting the scene for her current goal of helping organizations achieve their scientific and operational objectives efficiently and within compliance guidelines. She graduated from Dublin City University in 2001 with a BSc Hons. Analytical Science.</p></blockquote>

Waters Corporation: Empower Tips Ask Me Anything About Durable Data: A Guide to Ensuring Your Data Is Secure and Available from Creation Thru the Full Mandated Retention Period

Empower Tips Ask Me Anything About Durable Data: A Guide to Ensuring Your Data Is Secure and Available from Creation Thru the Full Mandated Retention Period

Protecting lab data is critical for compliance and financial health. Learn key strategies for secure retention, recovery, and cybersecurity in regulated labs.